Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, oxaliplatin, leucovorin and 5-fluoruracil, work in different ways separately and in combination to stop tumor cells from dividing so they stop growing or die. The use of metronomic dosing of chemotherapy minimizes side effects and increases efficacy by anti-angiogenic effects. The pilot study demonstrated promising responses in all patients. It is not yet known how effective this drug and dosing combination is in treating advanced pancreatic cancer. PURPOSE: This non-randomized phase II trial is studying giving weekly doses of paclitaxel, oxaliplatin, leucovorin and 5-fluorouracil together as second or third-line therapy in treating patient with locally advanced unresectable or metastatic adenocarcinoma of the pancreas following demonstrated progression after first-line gemcitabine.
Timeline
- Start
- 2006-05
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leucovorin | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 425 mg/m2 | Intravenous |
| Background | Calcium carbonate | Other / unclassified | 1 g | Intravenous |
| Background | Glutathione | Peptide | 1500 mg/m2 | Intravenous |
| Background | Magnesium Sulfate | Other / unclassified | 1 g | Intravenous |